Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed advanced malignancy, including the following:

  * Solid tumor that is refractory to standard therapy or for which no standard therapy exists

    * No lung carcinoma of squamous cell or small cell histology (mixed tumors will be categorized by the predominant cell type)

      * Histological confirmation based on sputum cytology alone is not acceptable
  * Lymphoma (Hodgkin or non-Hodgkin lymphoma) that has progressed after standard therapy AND for which stem cell transplantation is not indicated or has been refused
* No known CNS disease, except for treated brain metastasis meeting the following criteria:

  * No ongoing requirement for steroids
  * No evidence of progression or hemorrhage by clinical examination and brain imaging (MRI or CT scan) for ≥ 3 months after treatment

    * Stable dose of anticonvulsants allowed
  * Prior treatment for brain metastases may have included whole-brain radiotherapy, radiosurgery (gamma knife, linear accelerator, or equivalent), or a combination of therapy as deemed appropriate by the treating physician

    * Neurosurgical resection or brain biopsy for treatment of CNS metastases allowed provided treatment was completed more than 3 months ago

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
* Life expectancy \> 3 months
* Absolute neutrophil count ≥ 1,500/μL
* Platelet count ≥ 100,000/μL
* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* Creatinine \< 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
* Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection
* Activated partial thromboplastin time ≤ 1.5 times ULN
* Prothrombin time OR INR \< 1.5 times ULN
* Potassium between 4 mmol/L and ULN (supplementation allowed)
* Magnesium normal (supplementation allowed)
* Serum calcium (adjusted for albumin) or ionized calcium normal (supplementation allowed)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy
* HIV-positivity allowed provided the following criteria are met:

  * Patient does not require anti-HIV therapy
  * CD4 count \> 350/mm\^3
  * HIV viral load \< 25,000 copies/mm\^3
  * No history of opportunistic infections
* No evidence of severe or uncontrolled systemic disease or any concurrent condition that could compromise participation in the study, including any of the following:

  * Active or uncontrolled infection
  * Immune deficiencies
  * HIV infection requiring anti-HIV therapy
  * Hepatitis B
  * Hepatitis C
  * Uncontrolled diabetes
  * Uncontrolled hypertension
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Myocardial infarction within the past 6 months
  * Uncontrolled cardiac arrhythmia
  * Stroke/cerebrovascular accident within the past 6 months
  * Psychiatric illness/social situation that, in the investigator's opinion, would make it undesirable for the patient to participate in the study or that would jeopardize study compliance
* No New York Heart Association class III or IV heart disease within the past 6 months
* No history of arrhythmia (i.e., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment

  * Atrial fibrillation allowed provided it is controlled with medication
* No asymptomatic sustained ventricular tachycardia
* No other cardiac disease that, in the investigator's opinion, would increase the risk of ventricular arrhythmia
* QTc \< 480 msec (with measurable Bazett correction) by screening ECG
* No history of QTc prolongation as a result of other medications that required discontinuation
* No congenital long QT syndrome
* No first-degree relative with unexplained sudden death at under 40 years of age
* No left bundle branch block
* No hypertension not controlled by medical therapy, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg despite optimal medical management
* No other clinically significant cardiac event
* No thromboembolic disease within the past 6 months
* No significant vascular disease (e.g., aortic aneurysm or aortic dissection) or clinically significant peripheral vascular disease
* No serious non-healing wounds (including wounds healing by secondary intention)
* No acute or non-healing ulcers
* No bone fractures within the past 3 months
* No abdominal fistula, gastointestinal perforation, or intra-abdominal abscess within the past 28 days
* No currently active diarrhea that may affect the ability of the patient to absorb or tolerate vandetanib
* No hemoptysis (bright red blood of ≥ ½ teaspoon per episode) within the past 3 months
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior anti-VEGF therapy allowed
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
* More than 4 weeks since prior major surgery and recovered
* At least 2 weeks since prior investigational drugs given in a phase 0 clinical trial
* More than 10 days since prior and no concurrent aspirin (\> 325 mg/day) or chronic use of other NSAIDs
* No concurrent regular, therapeutic anticoagulation
* No concurrent medication that may cause QTc prolongation, induce Torsades de Pointes, or induce CYP3A4 function, including any of the following:

  * Rifampin
  * Rifabutin
  * Phenytoin
  * Carbamazepine
  * Phenobarbital
  * Hypericum perforatum (St. John's wort)
* No other concurrent antineoplastic therapy, except for gonadotropin-releasing hormone therapy for prostate cancer